Bill Text: IL HB2631 | 2023-2024 | 103rd General Assembly | Introduced

---

Bill Title: Amends the Medical Assistance Article of the Illinois Public Aid Code. Provides that for the purpose of removing barriers to the timely and equitable treatment of hepatitis C, prior authorization mandates and utilization management controls shall not be imposed under the fee-for-service and managed care medical assistance programs on any FDA-approved direct-acting antivirals for the treatment of hepatitis C that are listed as preferred on the Illinois Medicaid Preferred Drug List.

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Introduced) 2023-05-19 - Rule 19(a) / Re-referred to Rules Committee [HB2631 Detail]

Download: Illinois-2023-HB2631-Introduced.html

---

103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB2631 Introduced , by Rep. Marcus C. Evans, Jr. SYNOPSIS AS INTRODUCED:
305 ILCS 5/5-5.12f new
Amends the Medical Assistance Article of the Illinois Public Aid Code. Provides that for the purpose of removing barriers to the timely and equitable treatment of hepatitis C, prior authorization mandates and utilization management controls shall not be imposed under the fee-for-service and managed care medical assistance programs on any FDA-approved direct-acting antivirals for the treatment of hepatitis C that are listed as preferred on the Illinois Medicaid Preferred Drug List.
LRB103 26141 KTG 52498 b
A BILL FOR
HB2631 LRB103 26141 KTG 52498 b
AN ACT concerning public aid.
Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
Section 5. The Illinois Public Aid Code is amended by
adding Section 5-5.12f as follows:
(305 ILCS 5/5-5.12f new)
Sec. 5-5.12f. Prescription drugs for hepatitis C virus; no
prior approval mandates or utilization management controls.
Notwithstanding any other provision of this Code to the
contrary, for the purpose of removing barriers to the timely
and equitable treatment of hepatitis C, prior authorization
mandates and utilization management controls shall not be
imposed under the fee-for-service and managed care medical
assistance programs on any FDA-approved direct-acting
antivirals for the treatment of hepatitis C that are listed as
preferred on the Illinois Medicaid Preferred Drug List.